blog
Сүүлд шинэчилсэн: 2017-02-18

(Хорт хавдрын мэдлэг) Анхаарах ёстой биеийн арван сэрэмжлүүлгийн шинж тэмдэг

S
Medical Supporter баг
Олон улсын эмнэлгийн зохицуулалт ба нийтлэлийн хяналтын баг
(Хорт хавдрын мэдлэг) Анхаарах ёстой биеийн арван сэрэмжлүүлгийн шинж тэмдэг

(Cancer Knowledge) Ten Body Warning Signs to Watch For

Medical Supporter — Мэдээллийн мэдэгдэл

Энэ нийтлэл нь олон улсын эмнэлгийн мэдээллийн эмхэтгэл бөгөөд эмнэлгийн зөвлөгөө биш; таны эмчийн оношлогоо, эмчилгээний төлөвлөгөөг орлохгүй. Энд буй мэдээлэл нь Японы томоохон эмнэлгийн байгууллагуудын нээлттэй эх сурвалжаас эмхэтгэсэн бөгөөд аливаа эмчилгээний тохиромж, үр дүн өвчтөн бүрээр өөр тул мэргэшсэн эмч тус бүрчлэн үнэлэх ёстой.

Тодорхой эмчилгээний төлөвлөгөөг Японд лицензтэй эмч үнэлэх ёстой
  • March 23, 2020
  • 2 min read

1. Why Are the Ten Cancer Warning Signs Important?

With the advancement of modern medicine, effective screening methods and treatments are now available for many cancers. Because certain cancer risk factors have been identified, we can take measures to reduce the likelihood of occurrence. In addition to avoiding known risk factors, early detection of abnormal warning signs, immediate medical evaluation, and prompt treatment can significantly increase chances of recovery and survival.

2. The Ten Cancer Warning Signs — Seek Medical Attention Immediately If You Experience Any of the Following

  • Changes in bowel or bladder habits: Sudden increase or decrease in urinary or bowel frequency, especially sudden constipation, diarrhea, pencil-thin stools, frequent urination, urinary difficulty, or abnormal color or content in urine or stool. These warrant further evaluation of the rectum, bladder, or prostate.

  • A sore that does not heal: Body wounds normally heal within one week. Any wound that does not heal within two weeks requires attention, particularly ulcers in the mouth, throat, skin, nipple, or vagina.

  • Unusual bleeding or discharge: Unexplained bleeding or bruising anywhere in the body, such as nosebleeds, ear discharge, or vaginal bleeding.

  • A thickening or lump in the body: Lumps may appear in the neck, breast, abdomen, or groin area. Lumps are usually painless. Be alert to the possibility of nasopharyngeal carcinoma, breast cancer, lung cancer, neuroblastoma, or liver cancer.

  • Difficulty swallowing or chronic indigestion: Difficulty eating, loss of appetite, or persistent indigestion. Evaluate the throat, esophagus, or stomach.

  • Obvious change in a wart or mole: Redness, swelling, or visible change in a mole or wart on the skin. Be alert to the possibility of melanoma.

  • Nagging cough or hoarseness: Persistent cough, coughing up blood, or hoarseness. Perform further evaluation of the mouth, throat, and lungs.

  • Unexplained body pain: Persistent pain in a specific body area that does not improve over time.

  • Unexplained weight loss: In the absence of diabetes or hyperthyroidism, losing 2 kg within two weeks or 5 kg within one month without intentional dieting or exercise warrants investigation.

  • Unexplained prolonged fever or generalized fatigue.

Maintaining good body awareness through regular health check-ups, staying alert to changes, correcting unhealthy habits, and detecting potential disease factors early enables timely treatment and supports long-term good health.


Electric Field Cancer Therapy (ECCT) — Cancer Adjuvant Treatment in Japan

ECCT is generally ineffective on normal cells because tumor cells have different electrical properties (conductivity and permittivity) than normal cells. Tumor cells are more sensitive to external electric fields. Side effects are minimal compared to chemotherapy, with no major adverse events reported.

Treatment duration is determined by the physician after clinical observation and ongoing assessment.

A diet sufficient in albumin, vitamin C, flavonoids, and olive oil is recommended to support immune system function.

ECCT technology was developed by Professor Warsito P. Taruno and the CTech Laboratory team of Edward Technology (Indonesian Patent No. REGP00201200092, 2012).

  • Cancer Care

    • (NSCLC, Gastric, Pancreatic, Colorectal Cancer) ADLUMIZ: Japan's First Drug to Improve Cancer Cachexia Symptoms
    • TearExo: Detect Breast Cancer From a Single Tear — Results in as Little as 10 Minutes
    • (Cancer Care) Understanding Colorectal Cancer

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Японд эмчлүүлэхээр төлөвлөж байна уу? Мэдээлэл, тусламж хэрэгтэй юу?

Бид Японд эмчлүүлэхэд шаардлагатай мэдээллийг эмхэтгэх, Японы эмнэлгийн байгууллагуудтай холбогдох, хоёр дахь саналын зөвлөгөө зохион байгуулахад тусална.Анхны зөвлөгөө үнэгүй; зөвлөх таны дараагийн алхмыг тодорхой болгоход тусална.

Фукуока төв оффис: +81-92-409-5655
Өмнө нь албан ёсоор баталгаажсан, B-066 дугаар

Figure 1Figure 1

Figure 2Figure 2

Холбогдох уншлага

(лейкеми) Effectiveness -ийн Ibrutinib + Venetoclax?

Both BTK саатуулагч Ibrutinib monotherapy ба хавсарсан BCL2 саатуулагч Venetoclax + other treatments, without appropriate selection based дээр өвчтөн biological characteristics, байж болно lead руу unnecessary эмийн бэлдмэл ба economic losses.

2019-03-08

давшилтат Solid Tumors: Pembrolizumab зөвшөөрөл -д зориулсан TMB-High давтамжтай өвчин - Япон

February 25, 2022, Япон regulatory зөвшөөрөл -ийн pembrolizumab -д зориулсан TMB-high solid tumors after хими эмчилгээ бүтэлгүйтэл, expanding дархлаа эмчилгээ indication based дээр хавдар mutational burden биомаркер.

2024-09-15

ASCO 2016 тойм: Нойр булчирхайн хорт хавдрын туслах химийн эмчилгээний дэвшил

ASCO 2016-д PRODIGE 24 туршилт болон нойр булчирхайн хорт хавдрын бусад туслах эмчилгээний талаарх ойлголт. Япон улсаас мэргэжлийн онкологийн шинэчлэлүүд.

2015-11-06

(нойр булчирхайн хорт хавдар) үр дүнтэй -ийн Gemzar + Abraxane?

NEOLAP 2-р үе шат клиник туршилт evaluated gemcitabine нэмэх nab-paclitaxel ба FOLFIRINOX as induction хими эмчилгээ -д previously untreated locally давшилтат нойр булчирхайн хорт хавдар өвчтөнүүд, -тай хамт conversion rate as primary endpoint.

2018-10-01